Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
desacetylvinblastine hydrazide
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Desacetylvinblastine hydrazide is a potent vinca alkaloid derivative and a chemotherapy drug. It serves as the cytotoxic payload in antibody-drug conjugates like Vintafolide. Its mechanism of action involves binding to tubulin, which disrupts microtubule assembly-disassembly dynamics, leading to the inhibition of cell division (M phase-specific cell cycle arrest) and ultimately inducing apoptosis in mitotically active cells.
- Other names
- desacetylvinblastine monohydrazideDAVBH4-desacetylvinblastine-3-carboxhydrazide
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on desacetylvinblastine hydrazide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on desacetylvinblastine hydrazide.